308, F867F877
Semaglutide use was associated with a 36% lower risk, and liraglutide with a 28% lower risk
10.1371/journal.pone.0257606 106 TakiarV.CaplanM
Klausen MK, Justesen SK, Pedersen JN, Rasmussen L, Jensen A, Jensen ME, Knorr UB, Bergmann ML, Holst JJ, Hartmann B, Koob GF, Benveniste H, Volkow ND, Ekstrm CT, Knudsen GM, Vilsbll T, Fink-Jensen A
Ishy PL, Fagerlund B, Broberg BV, Bak N, Knop FK, Glenthj BY, et al
nausea decreases with ongoing usage a steady weight loss occurs in some patients over 2 years (may be related to nausea & CNS-mediated loss of appetite) there is an increased risk of hypoglycemia when exenatide is used with a sulfonylurea The dose of the sulfonylurea may need to be reduced if hypoglycemia occurs when combined with exenatide Most serious : rare & sometimes fatal necrotizing or hemorrhagic pancreatitis When initiating patients on Byetta, watch for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by vomiting)